Abstract 3622
Background
About 2-4% of patients with newly diagnosed multiple myeloma (MM) present with severe dialysis required renal failure (RF), which is associated with significant morbidity and early death. The aim of this article was to analyze own experience in treating this category.
Methods
During 10.2014-12.2017 the sixty-two patients with severe RF with a glomerular filtration rate (eGFR) <30 ml/min/1.73m2 were enrolled in this retrospective study. All patients received bortezomib-based regimens: 41 (66.1%) VDC; 2 (3.2%) PAD; 12 (19.4%) VD and 7 (11.3%) VMP. Seven (11.3%) patients underwent high-dose therapy with ASCT. IMWG (2010) renal response criteria were used. Myeloma response was evaluated using the standard IMWG (2006) criteria.
Results
At the time of presentation 48 (77%) patients required dialysis. The mean eGFR was 6.0 (95% CI 4.4-7.6) for patients requiring dialysis (Group A) and 22.2 (16.4-29.2) ml/min/1.73 m2 for those (Group B) are a dialysis independent (P < 0.001). Mean level of involved free light chain (iFLC) was 7400 (3440-10840) mg/l vs 2900 (780-5020) mg/l respectively (P < 0.001). The median time from RF to start of MM chemotherapy comprise 39 and 21 days for two groups respectively. Six (9.7%) patients died within the first 60 days of therapy (induction mortality). At least minimal renal response ( > =MRrenal) documented in 23.5% and 57.1% patients respectively. If the duration RF before initiation of MM treatment was >1 month no one patient required dialysis restored a renal function. Among all patients, overall myeloma response ( > =PR) documented in 81% cases, including 39.6% very good partial response (VGPR) and 14.6% complete response (CR/sCR). Two-years overall survival (OS) was 67.8 ± 6.4% without any different between groups.
Conclusions
In conclusion, our data indicate that bortezomib-based triplets are associated with a significant probability of renal response. In at least a 23.5% of patients with MM presenting with dialysis-requiring severe RF may improve their renal function and discontinue dialysis. Unfortunately, our results are inferior to the literature data according to which up to 50% of patients become independent of dialysis.
Clinical trial identification
Legal entity responsible for the study
Evgeniya Zhelnova.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract